Expert Point of View: European Perspective

Get Permission

3.2.47_andre.jpgECCO President Michael Baumann, MD, said that the findings on changes in receptor status throughout breast cancer progression were of major importance, “because many patients do not receive optimal treatment for their disease. The price of regular biopsies may seem high, but in the long run they may avoid inappropriate and costly treatment, and, even more importantly, may be the basis for selecting more effective treatments for an individual patient.”

According to Fabrice André, MD, Institut Gustave-Roussy, Villejuif, France, “The study further underlines the importance of taking regular biopsies in patients who relapse so that they can be sure of getting the most appropriate treatment, and of running trials looking at the relationship between the profiles of metastatic lesions and new specifically targeted agents.” ■

Disclosure: Dr. André reported no potential conflicts of interest.

Related Articles

Changes in Receptor Status during Breast Cancer Progression Warrant Rebiopsies at Relapse

Oncologists should be aware that common clinical tumor markers (denoting hormonal and HER2 status) change as breast cancer progresses, because these changes can affect treatment selection. Estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor status was changed from the time of the...

Expert Point of View: U.S. Perspective


“The practice of rebiopsy at relapse and metastasis is becoming increasingly common in the United States,” said Hope Rugo, MD, Professor at the University of California, San Francisco.

“More than 20% of patients have differing results from the primary tumor to rebiopsy at disease progression. It ...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.